Bibliographies thématiques / Analisi costo-efficacia / Articles de revues
Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Analisi costo-efficacia.

Articles de revues sur le sujet « Analisi costo-efficacia »

Auteur : Grafiati
Publié le 9 mars 2023
Mis à jour le 11 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 32 meilleurs articles de revues pour votre recherche sur le sujet « Analisi costo-efficacia ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Matarese, Alessandro, Pier Giorgio Calò, Gabriele Materazzi, Viola Villardita, Maurizio Iacobone, Antonella Pino, Paolo Carcoforo et al. « Analisi costo-efficacia del neuromonitoraggio nella chirurgia della tiroide ». L'Endocrinologo 23, no 3 (juin 2022) : 290–96. http://dx.doi.org/10.1007/s40619-022-01085-6.

Texte intégral
Résumé :
SommarioVi sono prove sempre più rilevanti circa l’importanza di una più dettagliata valutazione dei costi delle nuove tecnologie usate in chirurgia. L’impatto innovativo della tecnologia ha il potenziale per ottenere miglioramenti clinici rivoluzionari. Tuttavia, esistono informazioni limitate sul tema costo-efficacia delle nuove strategie chirurgiche usate in chirurgia tiroidea. In questo studio descriviamo le recenti evidenze relative ai metodi di valutazione costo-efficacia delle strutture e delle funzioni per il neuromonitoraggio intraoperatorio (IONM) in chirurgia tiroidea. I nostri risultati suggeriscono che il modello di economia sanitaria, nell’elaborazione della struttura degli studi costo-efficacia relativi al neuromonitoraggio intraoperatorio, si è dimostrata realizzabile come metodo per migliorare l’efficacia della ricerca.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Iannazzo, Sergio, Lorenzo Pradelli, Roberto W. Dal Negro et Mario Eandi. « Analisi di costo efficacia nella terapia della BPCO ». Farmeconomia. Health economics and therapeutic pathways 6, no 4 (15 décembre 2005) : 277–87. http://dx.doi.org/10.7175/fe.v6i4.843.

Texte intégral
Résumé :
Current practice guidelines for the treatment of COPD recommend the use of combined inhaled corticosteroids and long-acting bronchodilators in severe and very severe patients (GOLD stages III and IV). OBJECTIVES: To analyze the economical and clinical impact of this recommendation, the affordability of its widespread application, as well as the relative pharmacoeconomical performance of the available options for severe and very severe COPD in Italy. METHODS: Published data on the Italian COPD population were fitted in a disease progression model based on a Markov chain representing severity stages and death. Alternative therapeutic options (salmeterol/ fluticasone - SF, formoterol/budesonide - FB, salmeterol alone - S, fluticasone alone - F and control - C) were represented as competing arms in a decision tree. Efficacy data from international trials were expressed in terms of risk reduction. Clinical parameters used were number of exacerbations and symptom-free days. Direct and indirect costs were considered and valued according to present prices and tarifs. The analyses were conducted from National Health System, societal and patient perspectives with time horizons of 1,5, and 10 years, and lifelong. RESULTS: The yearly total direct costs of treating COPD patients in Italy is estimated in approximately 7 billion Euro, with a mean cost/patient/year around 2,400 Euro. Mean survival of the cohort is 11,5 years. The C and F strategies are dominated (i.e. are associated with worse outcomes and higher costs) by all alternatives. S/F and F/B are the most effective strategies, with a slight clinical superiority of the latter, but are also marginally more expensive than S. Incremental cost/effectiveness of S/F vs. S is 679,55 Euro/avoided exacerbation and 3,31Euro/gained symptom-free day. CONCLUSIONS: The recommended use of combined inhaled corticosteroids and long-acting bronchodilators for severe and very severe COPD patients, as compared with current practice, has the potential of improving clinical outcomes without increasing health care costs.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Berto, Patrizia, M. Breccia et R. Latagliata. « Analisi costo-efficacia di dasatinib nella prospettiva del SSN italiano ». Giornale Italiano di Health Technology Assessment 3, no 1 (juillet 2010) : 13–29. http://dx.doi.org/10.1007/bf03320729.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Bondonio, Piervincenzo. « Le analisi costo della malattia e costo efficacia in farmacoeconomia. Ambiti di applicabilità, problemi, prospettive ». Farmeconomia. Health economics and therapeutic pathways 1, no 1 (15 mars 2000) : 9–18. http://dx.doi.org/10.7175/fe.v1i1.707.

Texte intégral
Résumé :
Aim of the paper is to compare and evaluate some of the main features of two different tecniques of economic analyses: cost of illness e and cost-effectiveness. The former is not so widely used in pharmacoeconomics, while the latter is dominant. Although their theory has recently much progressed, their practice is still hindered by some unresolved questions, to which the paper also addressess.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Eandi, Mario, Nicola Giotta et Gaia Santagostino Barbone. « Analisi costo/efficacia di sevelamer nel trattamento dell’iperfosforemia del paziente in dialisi ». Farmeconomia. Health economics and therapeutic pathways 5, no 4 (15 décembre 2004) : 201–18. http://dx.doi.org/10.7175/fe.v5i4.809.

Texte intégral
Résumé :
Dialysis-associated hyperphosphatemia has been treated with chelating calcium salts, in particular with calcium carbonate. A new option for the management of this problem is represented by sevelamer, a chelating agent which contains no calcium and no metals. Sevelamer and calcium carbonate are more or less equally effective and tolerated. The prolonged use of sevelamer instead of calcium carbonate, nevertheless, reduces calcemia and C-reactive protein levels, with a consequent reduction in myocardial infarction, angina pectoris and other peripheral vasculopathies. The limit to the wide-spread use of sevelamer is in its very high acquisition cost, as compared to the alternative. In this article, a semi-markovian pharmacoeconomical model for the comparison of clinical and economical outcomes of sevelamer and calcium carbonate is presented. The analysis is conducted in the perspective of the Italian health system (SSN). Clinical data are derived from published studies and integrated with expert panel estimates, cost data are relative to the Italian setting. The incremental cost-effectiveness analysis indicated that sevelamer is more costly, but also more costeffective: a one month gain in survival costs the SSN additional 2710 Euro, a value inferior to the conventionally accepted willingness-to-pay of industrialised countries. The majority of this excess cost is derived from the gain in survival, and consequent increase in dialysis costs. Thus, the choice of using sevelamer instead of calcium carbonate is even more justified from an ethical point of view. Sensibility analyses confirmed the robustness of the basic scenario results.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Eandi, Mario, Elisa Berno et Lorenzo Pradelli. « Analisi costo/efficacia della doxofillina vs. teofillina nella terapia dell’asma cronica reversibile dell’adulto ». Farmeconomia. Health economics and therapeutic pathways 3, no 2 (15 juin 2002) : 103–17. http://dx.doi.org/10.7175/fe.v3i2.748.

Texte intégral
Résumé :
Doxofylline is a methyl-xanthine with bronchodilator activity which clinical efficacy in the treatment of asthma and COPD is equivalent to theophylline. Clinical trials prooved that while doxofylline is as effective as theophylline in the treatment of asthma, it is associated with lesser side effects. For our pharmacoeconomical evaluation, we employed the data of an international multi-centric study that compared the efficacy and tolerability of 12 weeks of treatment with either theophylline 250 mg tid, or doxofylline 400 mg tid, or placebo. The efficacy was evaluated with pulmonary function tests and by recording the number of asthma attacks and beta-2 agonist puffs: doxofylline 1200 mg/day and theophylline 750 mg/day resulted equally effective, but the former resulted better tolerated, as the adverse effects were lesser in number and severity. We performed a cost/effectiveness analysis in order to compare the two treatments, considering the perspective of the Italian health system (SSN) and of the Italian society. For the purposes of this analysis, the efficacy indices we considered were two: one simple, consisting in the number of avoided asthma attacks (AAA), and a more complex one, i.e. UATD (Utility Adjusted Therapy Days). For the construction of this index, we extracted the survival curve of the patients remaining in therapy; this curve showed that the cumulative number of therapy days is significantly greater in the doxofylline group, although the percentage of dropouts is similar at the end of the three months: this is due to the fact that the drop-outs in the theophylline group occur earlier after treatment start. The number of therapy days was then weighed for an utility index inversely proportional to the main daily number of avoided asthma attacks, thus obtaining the UATDs. The results of the cost/effectiveness analyses showed that doxofylline dominates theophylline treatment in asthma, as it is less expensive and more effective (in terms of AAAs and UATDs) for both considered decision-makers, i.e. Italian SSN and society. The consistency of these results was further confirmed by oneway sensitivity analyses.
Styles APA, Harvard, Vancouver, ISO, etc.
7

Franzosi, Maria Grazia, A. P. Maggioni, E. Santoro, G. Tognoni et E. Cavalieri. « Analisi costo-efficacia dell’impiego precoce di lisinopril nei pazienti con infarto miocardico acuto ». PharmacoEconomics Italian Research Articles 2, no 1 (septembre 2000) : 43–52. http://dx.doi.org/10.1007/bf03320573.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Russo, Pierluigi, E. Attanasio, O. Leri, F. Fiocca et G. I. Togna. « Analisi costo-efficacia di due combinazioni sequenziali di trattamenti di eradicazione dell’Helicobacter pylori ». PharmacoEconomics Italian Research Articles 3, no 1 (mars 2001) : 15–25. http://dx.doi.org/10.1007/bf03320576.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Standaert, B., A. Marocco, B. Assael, G. Gabutti, A. Guarino, P. L. Lopalco, Federico Marchetti et al. « Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus ». PharmacoEconomics Italian Research Articles 10, no 1 (mars 2008) : 23–35. http://dx.doi.org/10.1007/bf03320638.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Berto, P., A. Morsanutto, S. Lopatriello, M. Martelli, G. Muti, G. Santini et U. Vitolo. « Analisi costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linfoma non-Hodgkin aggressivo ». PharmacoEconomics Italian Research Articles 6, no 3 (novembre 2004) : 151–60. http://dx.doi.org/10.1007/bf03320633.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
11

Baio, Gianluca, et Pierluigi Russo. « Un modello di analisi del valore dell’informazione per la valutazione di costo-efficacia nell’ambito del processo regolatorio ». PharmacoEconomics Italian Research Articles 12, no 1 (mars 2010) : 5–16. http://dx.doi.org/10.1007/bf03320526.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
12

Lazzaro, C., P. Ruffo et M. Gozzo. « Analisi costo-efficacia dell’associazione budesonide/formoterolo come terapia di mantenimento e “al bisogno” nella gestione dell’asma. Valutazione italiana ». PharmacoEconomics Italian Research Articles 11, no 1 (mars 2009) : 39–53. http://dx.doi.org/10.1007/bf03320656.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
13

Olivares, Josè M., Alfonso Rodriguez-Martinez, Josè A. Buron, David Alonso-Escolano et Alexander Rodriguez-Morales. « Analisi costo-efficacia dello switch da un trattamento antipsicotico a risperidone iniettabile a rilascio prolungato in pazienti con schizofrenia ». Giornale Italiano di Health Technology Assessment 1, no 1 (janvier 2008) : 39–48. http://dx.doi.org/10.1007/bf03320712.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
14

Oliveri, C., F. Polcaro et R. Ravasio. « Analisi economica di exenatide rispetto a liraglutide nei pazienti con diabete di tipo 2 : costo-efficacia e budget impact ». Giornale Italiano di Health Technology Assessment 3, no 2 (septembre 2010) : 73–79. http://dx.doi.org/10.1007/bf03320735.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
15

Lucioni, Carlo, S. Mazzi et K. Neeser. « Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia ». PharmacoEconomics Italian Research Articles 6, no 2 (juillet 2004) : 81–93. http://dx.doi.org/10.1007/bf03320626.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
16

Ravasio, Roberto, N. Giotta, A. Marino, M. Colombo, F. Caligaris, G. Cesano, A. Grill, D. Sassone et E. Biamino. « Analisi costo-efficacia di cinacalcet più terapia standard versus terapia standard nel trattamento dei pazienti in dialisi con iperparatiroidismo secondario ». PharmacoEconomics Italian Research Articles 10, no 1 (mars 2008) : 13–22. http://dx.doi.org/10.1007/bf03320637.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
17

Ravasio, Roberto. « Analisi di costo efficacia di trastuzumab nel trattamento adiuvante del carcinoma mammario precoce HER-2 positivo : l’esperienza della Regione Toscana ». Giornale Italiano di Health Technology Assessment 2, no 3 (septembre 2009) : 89–98. http://dx.doi.org/10.1007/bf03320724.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
18

Marchetti, Monia, et Giorgio Lorenzo Colombo. « Considerazioni cliniche ed economiche nel trattamento del cancro della prostata : analisi costo-efficacia di bicalutamide vs flutamide in combinazione con LHRH ». Farmeconomia. Health economics and therapeutic pathways 4, no 3 (15 septembre 2003) : 153–68. http://dx.doi.org/10.7175/fe.v4i3.776.

Texte intégral
Résumé :
Prostate carcinoma (PC) is the most common malign neoplasm found in men over 65 years of age. In Italy, the incidence of this cancer is around 60/100,000/year, corresponding to about 11,000 new cases each year. Patients with PC consume health resources for a cost that is 10-24% higher than that of similar populations without PC. It is estimated that in Italy, each year, there are 19,000 hospitalizations for prostate cancer in patients over 65, a figure that represents 4% of the total hospitalizations for oncological diseases. We conducted a marginal cost/effectiveness analysis of bicalutamide vs. flutamide, both administered in combination with LHRH, in patients with advanced (metastatic) PC, on the basis of a randomized trial comparing 4 strategies of total androgenic blockade (TAB). The analysis was conducted in the perspective of the SSN (National health system). The comparison revealed that drug acquisition costs are not the only determinants of the economical differences between the two therapeutical strategies. Furthermore, we demonstrated that prolonged survival of the patients does not increase the consumption of health resources, since the chronological shift of the terminal phase reduces the value of the resources dedicated to it. When conducing the cost/effectiveness analysis, the survival advantage associated to bicalutamide has been adjusted to balance the low quality of life of PC patients. The pharmacoeconomical benefit of bicalutamide resulted of 12,150 Euro/QALY, while the cost per year of life saved resulted inferior, ranging from 8.327 to 11.440 Euro. This cost/QALY value is nevertheless lower than that associated to several therapeutical strategies that are commonly accepted in developed countries (domiciliar hemodialysis, heart transplantation, breast cancer screening, etc.). Considering that 12.150 Euro/QALY is the highest estimate of the relative cost/effectiveness of bicalutamide, it appears that the combination bicalutamide + LHRH represents an economically acceptable alternative to flutamide + LHRH in advanced PC patients.
Styles APA, Harvard, Vancouver, ISO, etc.
19

Eandi, Mario. « Analisi Costo-Efficacia di Amfotericina B Liposomiale (L-AmB) versus Amfotericina B Complesso Lipidico (ABLC) nel trattamento empirico della neutropenia febbrile ». Farmeconomia. Health economics and therapeutic pathways 6, no 4 (15 décembre 2005) : 333–47. http://dx.doi.org/10.7175/fe.v6i4.851.

Texte intégral
Résumé :
Current international guidelines for the management of immuno-compromised patients with febrile neutropenia recommend a systemic antimicrobial therapy if fever hasn’t receded after three days of antibiotic treatment. Amphotericin B remains the gold standard because of its broad spectrum fungicidal action and minimal resistance development risk. Nonetheless, therapeutic use of the standard formulation, Amphotericin B deoxycholate, is limited by its toxicity, especially on the kidneys. To counteract this, amphotericin B has been encapsulated in liposomes, a process which reduces its toxicity and allows higher doses to be given. Three lipid formulations have been developed and are now available in most countries: amB colloidal dispersion (ABCD), amB lipid complex (ABLC), and liposomal amB (L-AmB). These lipid formulations differ in pharmacodynamics and pharmacokinetics, and can’t therefore be considered interchangeable. Besides, they are more expensive than Amphotericin B deoxycholate. Aim of the study is to perform a cost/effectiveness analysis (CEA) comparing L-AmB (3mg/kg/die or 5mg/kg/ die) and ABLC (5mg/kg/die) as first-line antimicrobial empirical treatments in immuno-compromised patients with febrile neutropenia resistant to broad spectrum antibiotics. Secondly, we present a cost-minimization analysis (CMA) of the considered alternatives, assuming the same efficacy for all treatments. At the end we value the principal cost items from the point of view of the Italian Health Service, with a particular focus on the economic burden caused by adverse reactions.
Styles APA, Harvard, Vancouver, ISO, etc.
20

Rebesco, Barbara, Elena Cantagalli et Maria Elvira Amalfitano. « Analisi costo-efficacia di due schemi adiuvanti per il trattamento del carcinoma del colon-retto : lettura dei dati dello studio mosaic ». Tumori Journal 91, no 6 (novembre 2005) : 1–10. http://dx.doi.org/10.1177/030089160509100628.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
21

Ravasio, R., L. Sanfilippo, G. De Paoli, C. Cerra, P. Fratino et M. Della Giovanna. « Analisi di costo-efficacia dello switch da un antipsicotico orale a risperidone a rilascio prolungato nel trattamento dei pazienti affetti da schizofrenia ». Giornale Italiano di Health Technology Assessment 2, no 1 (mars 2009) : 1–8. http://dx.doi.org/10.1007/bf03320713.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
22

Castorina, Sebastiano Maurizio. « Rettifica al lavoro : considerazione cliniche ed economiche nel trattamento del cancro della prostata : analisi costo/efficacia di bicalutamide vs. flutamide in combinazione con LHRH ». Farmeconomia. Health economics and therapeutic pathways 5, no 1 (15 mars 2004) : 31–32. http://dx.doi.org/10.7175/fe.v5i1.787.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
23

Ravasio, R. « Analisi di costo-efficacia di exenatide versus insulina glargine nel trattamento dei pazienti diabetici di tipo 2 in fallimento secondario al doppio ipoglicemizzante orale ». Giornale Italiano di Health Technology Assessment 1, no 1 (janvier 2008) : 21–30. http://dx.doi.org/10.1007/bf03320710.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
24

Merli, F., Roberto Ravasio, I. Alvarez De Cielis et F. Polcaro. « Analisi di costo-efficacia di rituximab più CHOP versus ProMACE-CytaBOM nel trattamento del linfoma diffuso a grandi cellule B : l’esperienza di Reggio Emilia ». Giornale Italiano di Health Technology Assessment 2, no 2 (juin 2009) : 55–64. http://dx.doi.org/10.1007/bf03320719.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
25

Ravasio, Roberto. « Analisi di costo efficacia di emtricitabina/tenofovir disoproxil più efavirenz rispetto ad altri regimi antiretrovirali nel trattamento di prima linea di pazienti affetti da HIV ». Giornale Italiano di Health Technology Assessment 3, no 1 (juillet 2010) : 1–11. http://dx.doi.org/10.1007/bf03320728.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
26

Ravasio, Roberto. « Analisi di costo-efficacia di prasugrel rispetto a clopidogrel nel trattamento di pazienti con sindrome coronarica acuta e intervento di angioplastica per via percutanea programmato ». Giornale Italiano di Health Technology Assessment 3, no 2 (septembre 2010) : 55–63. http://dx.doi.org/10.1007/bf03320733.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
27

Ravasio, Roberto, et L. Guidi. « Analisi di costo-efficacia di pemetrexed più cisplatino versus gemcitabina più cisplatino nel trattamento di prima linea in pazienti con NSCLC non squamoso in stadio avanzato ». Giornale Italiano di Health Technology Assessment 2, no 2 (juin 2009) : 73–80. http://dx.doi.org/10.1007/bf03320721.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
28

Ravasio, R., L. Guidi, D. Valle, K. Taipale et Y. Asukai. « Analisi di costo-efficacia nel trattamento di prima linea con i regimi chemioterapici pemetrexed più cisplatino, gemcitabina più cisplatino e bevacizumab più gemcitabina più cisplatino in pazienti con NSCLC localmente avanzato o metastatizzato in Italia ». Giornale Italiano di Health Technology Assessment 2, no 3 (septembre 2009) : 99–109. http://dx.doi.org/10.1007/bf03320725.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
29

Macêdo, Karen Vanderlei. « Diritto alla salute : La legalizzazione della concessione di medicinali ad alto costo ». Revista Científica Multidisciplinar Núcleo do Conhecimento, 10 décembre 2020, 05–16. http://dx.doi.org/10.32749/nucleodoconhecimento.com.br/legge/diritto-alla-salute.

Texte intégral
Résumé :
Oggetto di analisi di questo articolo è l’intreccio tra il diritto alla salute in Brasile e l’attivazione della Corte Suprema Federale (STF) come garanzia di efficacia pratica, la legalizzazione della politica, in particolare, la concessione di farmaci ad alto costo. In vista del diritto alla salute in Brasile si scontrano due Principi, la riserva del possibile e il minimo esistenziale, che richiede, secondo Barroso (2009), una considerazione da parte dell’interprete della legge sulla ragionevolezza dei casi concreti. Al fine di verificare, in tema di diritto alla salute, abbiamo analizzato alcune Sentenze STF in materia, che appaiono sul suo sito web. Notiamo che c’è una preponderanza della riserva del possibile nelle decisioni della STF a scapito del minimo esistenziale.
Styles APA, Harvard, Vancouver, ISO, etc.
30

Ravasio, Roberto, M. P. Pedone et M. Ratti. « Analisi di costo efficacia dei nuovi anticoagulanti orali nella prevenzione dell’ictus in pazienti con fibrillazione atriale non valvolare in Italia ». PharmacoEconomics Italian Research Articles 16, no 2-3 (7 août 2014). http://dx.doi.org/10.1007/s40276-014-0022-x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
31

Ravasio, Roberto, M. P. Pedone et M. Ratti. « Erratum a : Analisi di costo efficacia dei nuovi anticoagulanti orali nella prevenzione dell’ictus in pazienti con fibrillazione atriale non valvolare in Italia ». PharmacoEconomics Italian Research Articles 17, no 1 (10 décembre 2014). http://dx.doi.org/10.1007/s40276-014-0024-8.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
32

« Costo-efficacia dell’aggiunta di empagliflozin alla terapia di pazienti diabetici con malattia renale negli Stati Uniti : analisi dei risultati dello studio EMPA-REG ». il Diabete 33, no 4 (2021). http://dx.doi.org/10.30682/ildia2104e.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie